{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:56:57Z","timestamp":1775638617848,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","jocn-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jocn.2018.01.024","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T05:56:45Z","timestamp":1519019805000},"page":"194-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome"],"prefix":"10.1016","volume":"50","author":[{"given":"Moon Kyu","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il Nam","family":"Sunwoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2018.01.024_b0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jocn.2018.01.024_b0010","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1212\/WNL.34.10.1324","article-title":"Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine","volume":"34","author":"Lundh","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2018.01.024_b0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF00386054","article-title":"Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine","volume":"234","author":"Lundh","year":"1985","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"10.1016\/j.jocn.2018.01.024_b0020","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.0000000000002466","article-title":"3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies","volume":"86","author":"Evoli","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2018.01.024_b0025","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2018.01.024_b0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann Thor Surg"},{"key":"10.1016\/j.jocn.2018.01.024_b0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0404.1993.tb04205.x","article-title":"Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome","volume":"88","author":"Lundh","year":"1993","journal-title":"Acta neurologica Scandinavica"},{"key":"10.1016\/j.jocn.2018.01.024_b0040","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1749-6632.1998.tb11022.x","article-title":"3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS)","volume":"841","author":"Sanders","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2018.01.024_b0045","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410120406","article-title":"Electrophysiological and clinical correlation in myasthenia gravis","volume":"12","author":"Oh","year":"1982","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2018.01.024_b0050","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/WNL.37.8.1411","article-title":"Overlap myasthenic syndrome: combined myasthenia gravis and Eaton-Lambert syndrome","volume":"37","author":"Oh","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2018.01.024_b0055","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.clinph.2004.12.013","article-title":"MG and LEMS overlap syndrome: case report with electrophysiological and immunological evidence","volume":"116","author":"Oh","year":"2005","journal-title":"Clin Neurophysiol: Off J Int Fed Clin Neurophysiol"},{"key":"10.1016\/j.jocn.2018.01.024_b0060","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.nmd.2015.04.012","article-title":"Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review","volume":"25","author":"Alboini","year":"2015","journal-title":"Neuromuscular Disorders: NMD."},{"key":"10.1016\/j.jocn.2018.01.024_b0065","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/(SICI)1097-4598(199912)22:12<1727::AID-MUS19>3.0.CO;2-K","article-title":"Lambert-Eaton myasthenic syndrome with ophthalmoparesis and pseudoblepharospasm","volume":"22","author":"Kanzato","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2018.01.024_b0070","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1212\/WNL.50.2.470","article-title":"Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome","volume":"50","author":"Katz","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2018.01.024_b0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3988\/jcn.2012.8.3.235","article-title":"A patient with coexisting myasthenia gravis and lambert-eaton myasthenic syndrome","volume":"8","author":"Kim","year":"2012","journal-title":"J Clin Neurol (Seoul, Korea)"},{"key":"10.1016\/j.jocn.2018.01.024_b0080","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3988\/jcn.2012.8.4.305","article-title":"A case of lambert-eaton myasthenic syndrome with small-cell lung cancer and transient increase in anti-acetylcholine-receptor-binding antibody titer","volume":"8","author":"Lee","year":"2012","journal-title":"J Clin Neurol (Seoul, Korea)"},{"key":"10.1016\/j.jocn.2018.01.024_b0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/CND.0b013e3181a347ff","article-title":"Myasthenia gravis with presynaptic electrophysiologic abnormalities","volume":"10","author":"Callaghan","year":"2009","journal-title":"J Clin Neuromuscular Dis"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586817313322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586817313322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T06:29:10Z","timestamp":1530599350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586817313322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":17,"alternative-id":["S0967586817313322"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2018.01.024","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2018.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}